目的 探討復(fù)方苦參注射液聯(lián)合索拉菲尼和白細(xì)胞介素-2治療晚期腎癌的臨床療效。方法 選擇2013年7月—2015年3月在中國(guó)醫(yī)科大學(xué)附屬盛京醫(yī)院接受治療的晚期腎癌患者86例,按照治療方法不同分為對(duì)照組和治療組,每組各43例。對(duì)照組于飯后2 h口服甲苯磺酸索拉非尼片,400 mg/次,2次/d。注射用重組人白細(xì)胞介素-2以3×10⁵ U/m²加入0.9%生理鹽水500 mL中經(jīng)PICC管滴注,靜滴2～3 h,1次/d,每周連用4 d,連用4周為1個(gè)療程。治療組在對(duì)照組治療基礎(chǔ)上經(jīng)PICC管滴注復(fù)方苦參注射液,20 mL加入到0.9%生理鹽水250 mL中,1次/d,1個(gè)療程連用14 d。4周為一個(gè)療程,兩組均連續(xù)治療3個(gè)療程。觀察兩組的臨床療效和生活質(zhì)量改善情況,同時(shí)比較兩組患者治療前后免疫功能的變化情況。結(jié)果 治療后,對(duì)照組有效率為20.93%,臨床獲益率為65.12%;治療組有效率為41.86%,臨床獲益率為83.72%,兩組有效率、臨床獲益率比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。對(duì)照組和治療組生活質(zhì)量改善率分別為67.44%、86.05%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺較治療前均有不同程度增高,CD⁸⁺水平降低,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05);治療后,治療組這些觀察指標(biāo)的改善程度優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 復(fù)方苦參注射液聯(lián)合索拉非尼和白細(xì)胞介素-2治療晚期腎癌療效較好,可改善患者的生活質(zhì)量和免疫功能,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Compound Kushen Injection combined with sorafenib and interleukin-2 in treatment of advanced kidney cancer. Methods Patients (86 cases) with advanced kidney cancer in Shengjing Hospital of China Medical University from July 2013 to March 2015 were enrolled in this study. According to the different treatment plan, patients were divided into treatment (43 cases) and control (43 cases) groups. The patients in the control group were po administered with Sorafenib Tosylate Tablets 2 h after meals, 400 mg/time, twice daily. They were also iv administered with Recombinant Human Interleukin-2 for injection by PICC tube during 2-3 h, 3 × 10⁵ U/m² added into normal saline 500 mL. The patients were treated with Recombinant Human Interleukin-2 for 4 d in one week, and 4 weeks were as one course. The patients in the treatment group were iv administered with Compound Kushen Injection by PICC tube on the basis of control group, 20 mL added into 0.9% normal saline 250 mL, once daily, 14 d in one course. One course of treatment included 4 weeks, and two groups were treated for three courses. The clinical efficacy and improvement of life quality in two groups were evaluated, and the changes of immune function in two groups before and after treatment were compared. Results After treatment, the total effective rate of control group was 20.93%, and the clinical benefit rate was 65.12%, while the total effective rate of treatment group was 41.86%, and the clinical benefit rate was 83.72%, and there were differences between two groups (P < 0.05). The improvement rate of life quality in the control and treatment groups were 67.44% and 86.05%, respectively, and there were differences between two groups (P < 0.05). After treatment, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ cell in two groups were increased, and the level of CD⁸⁺ cell was lower, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Compound Kushen Injection combined with sorafenib and interleukin-2 has the good clinical effect in treatment of advanced kidney cancer, and can improve the life quality and immune function, which has a certain clinical application value.